[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MXPA01012644A - Combinaciones antilipemicas que comprenden inhibidores de hmg-coa reductasa y carnitina. - Google Patents

Combinaciones antilipemicas que comprenden inhibidores de hmg-coa reductasa y carnitina.

Info

Publication number
MXPA01012644A
MXPA01012644A MXPA01012644A MXPA01012644A MXPA01012644A MX PA01012644 A MXPA01012644 A MX PA01012644A MX PA01012644 A MXPA01012644 A MX PA01012644A MX PA01012644 A MXPA01012644 A MX PA01012644A MX PA01012644 A MXPA01012644 A MX PA01012644A
Authority
MX
Mexico
Prior art keywords
carnitine
alkanoyl
acid
hmg
coa reductase
Prior art date
Application number
MXPA01012644A
Other languages
English (en)
Spanish (es)
Inventor
Paolo Carminati
Original Assignee
Sigma Tau Ind Farmaceutiche S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP99830415A external-priority patent/EP1064943B1/en
Application filed by Sigma Tau Ind Farmaceutiche S filed Critical Sigma Tau Ind Farmaceutiche S
Publication of MXPA01012644A publication Critical patent/MXPA01012644A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MXPA01012644A 1999-06-08 2000-06-05 Combinaciones antilipemicas que comprenden inhibidores de hmg-coa reductasa y carnitina. MXPA01012644A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13800899P 1999-06-08 1999-06-08
EP99830415A EP1064943B1 (en) 1999-06-30 1999-06-30 Combination having antilipemic activity substantially free from toxic or side effects due to antilipemic drugs
PCT/EP2000/005091 WO2000074675A1 (en) 1999-06-08 2000-06-05 Antilipemic combinations comprising hmg-coa reductase inhibitors and carnitines

Publications (1)

Publication Number Publication Date
MXPA01012644A true MXPA01012644A (es) 2002-07-22

Family

ID=26153794

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA01012644A MXPA01012644A (es) 1999-06-08 2000-06-05 Combinaciones antilipemicas que comprenden inhibidores de hmg-coa reductasa y carnitina.

Country Status (10)

Country Link
JP (1) JP2003501385A (sk)
KR (1) KR100725263B1 (sk)
AU (1) AU782188B2 (sk)
CA (1) CA2375378C (sk)
CZ (1) CZ20014218A3 (sk)
HU (1) HUP0201597A3 (sk)
MX (1) MXPA01012644A (sk)
PL (1) PL197899B1 (sk)
SK (1) SK285900B6 (sk)
WO (1) WO2000074675A1 (sk)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100029759A1 (en) * 2007-02-27 2010-02-04 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Composition useful for the treatment of type 2 diabetes
EP2136798B1 (en) * 2007-03-21 2015-07-29 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Composition useful for the prevention of type 2 diabetes and its complications in pre-diabetic patients with insulin resistance
CN102014896A (zh) * 2008-02-29 2011-04-13 生物实验萨纽斯药物有限公司 包含西坦和肉毒碱的药物组合物及其制备方法
US20120130202A1 (en) * 2010-11-24 2012-05-24 Fujitsu Limited Diagnosis and Monitoring of Musculoskeletal Pathologies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0667833B2 (ja) * 1985-11-28 1994-08-31 雪印乳業株式会社 経腸栄養剤
DE69001146T2 (de) * 1989-01-18 1993-10-07 Merck & Co Inc Koenzym Q10 mit HMG-COA-Reduktase-Inhibitoren.
IT1293067B1 (it) * 1997-07-01 1999-02-11 Sigma Tau Ind Farmaceuti Composizione farmaceutica per il trattamento di patologie causate da alterato metabolismo lipidico

Also Published As

Publication number Publication date
SK17152001A3 (sk) 2002-03-05
CA2375378A1 (en) 2000-12-14
CZ20014218A3 (cs) 2002-04-17
CA2375378C (en) 2009-08-11
SK285900B6 (sk) 2007-10-04
PL197899B1 (pl) 2008-05-30
PL352106A1 (en) 2003-07-28
JP2003501385A (ja) 2003-01-14
WO2000074675A1 (en) 2000-12-14
AU5969700A (en) 2000-12-28
KR20020025066A (ko) 2002-04-03
HUP0201597A3 (en) 2003-04-28
KR100725263B1 (ko) 2007-06-07
AU782188B2 (en) 2005-07-07
HUP0201597A2 (en) 2002-09-28

Similar Documents

Publication Publication Date Title
US20120014907A1 (en) Use of substituted cyanopyrrolidines and combination preparations containing them for treating hyperlipidemia and associated diseases
PT2704734E (pt) Composição útil para o tratamento de distúrbios do metabolismo de lípidos
US6245800B1 (en) Method of preventing or treating statin-induced toxic effects using L-carnitine or an alkanoyl L-carnitine
AU726822B2 (en) Pharmaceutical compositions comprising alkanoyl L-carnitine in combination with a statine for treating pathologies brought about by an altered lipid metabolism
MXPA01012644A (es) Combinaciones antilipemicas que comprenden inhibidores de hmg-coa reductasa y carnitina.
EP1064943B1 (en) Combination having antilipemic activity substantially free from toxic or side effects due to antilipemic drugs
CN113134086B (zh) 一种降血脂的药物组合物
CA2678746C (en) Composition useful for the treatment of type 2 diabetes
EP1699448A2 (en) Methods of administering 3,3,14,14 tetramethyl hexadecane 1,16 dioic acid
MXPA99011665A (en) Pharmaceutical compositions comprising alkanoyl l-carnitine in combination with a statine for treating pathologies brought about by an altered lipid metabolism
NZ542505A (en) Use of low molecular weight thrombin inhibitors in cholesterol-lowering therapy
NZ548902A (en) The use of substituted cyanopyrrolidines and combination preparations containing them for treating hyperlipidemia and associated diseases

Legal Events

Date Code Title Description
FG Grant or registration